Recommendations pharmacological tobacco cessation treatments: Proposals for financing;Recomendaciones para el tratamiento farmacológico del tabaquismo. Propuestas de financiación

Archivos de Bronconeumologia

Volumn 44, Issue 4, 2008, Pages 213-219

  Jiménez Ruiz, Carlos A ^a,k   Miranda, Juan Antonio Riesco ^b   Pinedo, Ángela Ramos ^c   Ferrero, Miguel Barrueco ^d   Reina, Segismundo Solano ^e   Orive, José Ignacio De Granda ^f   Guzmán, Jesús Grávalos ^g   Casado, Lourdes Ramos ^h   Trullén, Alfonso Pérez ⁱ   Fagerström, Karl O ^j  

^a Unidad Especializada en Tabaquismo ^*  (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^f HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^g HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^h HOSPITAL RÍO CARRIÓN   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^j Fagerstrom Consulting   (Sweden)

^k Escuela Nacional de Salud ENS   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; ALLERGIC REACTION; ARTHRALGIA; CLINICAL TRIAL; CONVULSION; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; ECZEMA; ERYTHEMA; FINANCIAL MANAGEMENT; FLATULENCE; HEADACHE; HEART PALPITATION; HEARTBURN; HICCUP; HUMAN; INSOMNIA; METEORISM; MYALGIA; NAUSEA; NICOTINE REPLACEMENT THERAPY; PARESTHESIA; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SMOKING CESSATION; TASTE DISORDER; TOBACCO DEPENDENCE; VIVID DREAM; XEROSTOMIA;

EID: 45549086694     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13119541     Document Type: Article

References (35)

1. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. Treating tobacco use and dependence. Clinical practice guideline. Rockville: US Department of Health and Human Services. Public Health Service; 2000.
2. Tønnesen P, Carrozzi L, Fagerström KO, Gratziou C, Jimenez-Ruiz CA, Nardini S, et al. Task Force recommendations: smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J. 2007;29:390-427.
3. Akehurst RL, Bernett D, Berry C, Bird S, Buxton M, Claxton K, et al. Guidance on the use of nicotine replacement therapy and bupropión for smoking cessation. National Institute for Clinical Excellence. Disponible: www.nice.org.uk
4. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Thorax. 2000;55:987-99.
5. Pérez Trullén A, Clemente Jiménez L. Presente y futuro de los tratamientos para dejar de fumar. Arch Bronconeumol. 2001;37:241-6.
6. Jiménez Ruiz CA, Barrueco Ferrero M, Solano Reina S, Torrecilla García M, Domínguez Granda F, Díaz-Maroto Muñoz JL, et al. Recomendaciones en el abordaje diagnóstico y terapéutico del tabaquismo. Documento de consenso. Arch Bronconeumol. 2003;39:35-41.
7. Jiménez Ruiz CA, Solano Reina S, González de Vega JM, Ruiz Pardo M, Flórez Martín S, Ramos Pinedo A, et al. Normativa para el tratamiento del tabaquismo. Arch Bronconeumol. 1999;335:499-506.
8. Jiménez Ruiz CA, Granda Orive JI, Solano Reina S, Carrión Valero F, Romero Palacios J, Barrueco Ferrero M. Recomendaciones para el tratamiento del tabaquismo. Arch Bronconeumol. 2003;39:409-18.
9. Cornuz J, Pinget C, Gilbert A, Paccaud F. Cost-effectiveness analysis of the first line therapies for nicotine dependence. Eur J Clin Pharmacol. 2003;59: 201-6.
10. De Granda Orive JI, Gutiérrez Jiménez T, Martínez Albiach JM. La financiación de los tratamientos para dejar de fumar a través del sistema nacional de salud puede incrementar su éxito. Arch Bronconeumol. 2006;42:666.
11. Fagerström KO, Balfour D. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs. 2006;15:107-16.
12. Cadoni C, Di Chiara G. Differential changes in the accumbens medial shell and core dopamine in behavioural sensitization to nicotine. Eur J Pharmacol. 2000;387:R23-R5.
13. Caggiula AR, Donny EC, Chaudrin N, Perkins KA, Evans Martin FF, Sved AF. Importance of nonpharmacological factors in nicotine self-administration. Physiol Behav. 2002;77:683-7.
14. Rose JE, Behn FM, Westmen EC, Johnson M. Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol Biochem Behav. 2000;67:71-81.
15. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146.
16. Fagerström KO, Jiménez Ruiz CA. Tratamiento farmacológico del tabaquismo. En: Jiménez Ruiz CA, Solano Reina S, editores. Monografías Neumomadrid. Tabaquismo. Madrid: Ergón; 2004. p. 101-10.
17. Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Joremby DE, Ryan CF, et al. Efficacy of acute administration of nicotine gum in relief of cue- provoked cigarette craving. Psychopharmacology. 2003;166:343-50.
18. Dautzenberg M. Multicentre controlled study with nicotine pills. Actas de 3rd SRNT European Conference; 2001; Paris.
19. Shiffman S, Fant R, Buchhalter R, Girchell J, Henningfield J. Nicotine delivery systems. Expert Opin Drug Deliv. 2005;2:563-77.
20. Rose JE, Behm FM, Westman EC, Kukovich P. Precesation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob Res. 2006;8:89-101.
21. Tonnessen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE-trial. Eur Respir. 1999;13:238-46.
22. Niaura R, Sayette MA, Shiffman S. Comparative efficacy of rapid-release nicotine gum vs. Nicorette in relieving smoking cue-provoked craving. Actas de Annual Meeting of the Society for Research on Nicotine and Tobacco; 2003, febrero 19-22; New Orleans. New Orleans: Society for Research on Nicotine and Tobacco; 2003.
23. Kornitzer M, Boutsen M, Dramaix M, Thijs JK, Gusstavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995;24:41-7.
24. Jiménez Ruiz CA, Fagerström KO. Reducción hasta dejarlo: árbol de decisión. Prev Tab. 2006;8 Supl 1:34-7.
25. Pisinger C, Vestbo J, Borch-Johnsen K, Jorgensen T. Smoking reduction intervention in a large population-based study. Prev Med. 2005;40:1128.
26. Bolliger CT, Zellweger J-P, Danielsson T, Van Biljon X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhalers: double blind, randomized clinical trial of efficacy and safety. BMJ. 2000;321:329-33.
27. Rennard SI, Glover E, Leischow S, Daughto DM, Glover PM, Muramoto M, et al. Efficacy of nicotine inhaler in smoking reduction: a double-blind, randomized trial. Nicotine Tob Res. 2006;8: 555-64.
28. Jiménez Ruiz CA, Fagerström KO. Un nuevo planteamiento del tratamiento del tabaquismo. Prev Tab. 2006; 8 Supl 1:1.
29. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH, Pinto A, et al. Effects of dopamine transporter and receptor polymorphins on smoking cessation in a bupropion clinical trial. Health Psychol. 2003;22:541-8.
30. Balfour D. The neurobiology of tobacco dependence: a pre-clinical perspective on the role of dopamine proyections to the nucleus accumbens. Nicotinet Tob Res. 2004;6:899-912.
31. Jarvis M, Powell S, Marsh H. A meta-analysis of clinical studies confirms the effectiveness of bupropion SR in smoking cessation. Actas de 7th Annual Conference of the Society for Research of Nicotine and Tobacco; 2001, marzo 23-25; Seattle. Seattle: Society for Research of Nicotine and Tobacco; 2001.
32. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Sys Rev. 2004;(4):CD000031.
33. Zierler-Brown SL, Kyle JA. Oral varenicline for smoking cessation. Ann Pharmacother. 2007;41:95-9.
34. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonist for smoking cessation. Cochrane Database Sys Rev. 2007;(1):CD006103.
35. Kaper J, Wagena EJ, Severens JL, Van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Sys Rev. 2005;(1):CD004305.